Arcoma AB
Research Arcoma AB (ARCOMA) on Bullrun: valuation model: 0.9% undervalued, market cap SEK 125.91M, P/E 33.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARCOMA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Valuation signal0.9% undervalued
- Market capSEK 125.91M
- P/E33.8
- Financial periodQ1 2026
- RevenueSEK 31.13M
- Net incomeSEK 811.00K
- Free cash flow-SEK 1.43M
- Gross margin40.0%
Valuation Snapshot
Bullrun's latest valuation model marks Arcoma AB as 0.9% undervalued; latest market cap is SEK 125.91M; P/E is 33.8.
About Arcoma AB
Arcoma AB develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. It also provides x-ray detectors; video bank;
Frequently asked questions
Is Arcoma AB overvalued or undervalued?
Bullrun's valuation model currently marks Arcoma AB as 0.9% undervalued.
What is Arcoma AB's market cap?
Arcoma AB's market capitalization is SEK 125.91M.
What is Arcoma AB's P/E ratio?
Arcoma AB's price-to-earnings (P/E) ratio is 33.8.
What does Arcoma AB do?
Arcoma AB develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics.